

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4685588

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	IVAN COULTER	11/11/2010
RECEIVING PARTY DATA		
Name:	SIGMOID PHARMA LIMITED	
Street Address:	INVENT CENTRE	
Internal Address:	DUBLIN CITY UNIVERSITY	
City:	DUBLIN	
State/Country:	IRELAND	
Postal Code:	9	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	13441780
CORRESPONDENCE DATA		
Fax Number:	(503)595-5301	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	503-595-5300	
Email:	morgan.rafalski@klarquist.com	
Correspondent Name:	KLARQUIST SPARKMAN, LLP	
Address Line 1:	121 SW SALMON ST., SUITE 1600	
Address Line 2:	ONE WORLD TRADE CENTER	
Address Line 4:	PORTLAND, OREGON 97204	
ATTORNEY DOCKET NUMBER:	8365-83989-02	
NAME OF SUBMITTER:	WAYNE RUPERT	
SIGNATURE:	/Wayne Rupert/	
DATE SIGNED:	11/13/2017	
Total Attachments: 5		
source=Assignment#page1.tif		
source=Assignment#page2.tif		
source=Assignment#page3.tif		
source=Assignment#page4.tif		

THIS ASSIGNMENT IS MADE the *11th* day of *November* 2010

BETWEEN

1. **Ivan Coulter**, of 11 St. Anne's, Northbrook Road, Ranelagh, Dublin 6, Ireland, formerly of 21 Leeson Street, Dublin 2, Ireland "the Inventor"; and
2. **Sigmoid Pharma Limited** formerly Sigmoid Biotechnologies Limited ("Sigmoid Pharma"), an Irish company whose registered office is at Invent Centre, Dublin City University, Dublin 9, Ireland.

Introduction

- A. The Inventor is the devisor of inventions ("the Inventions") which are the subject of the patent applications and/or patents listed in Schedule A attached hereto ("the Applications").
- B. When the Inventor devised his contributions to the Inventions, Sigmoid Pharma (formerly Sigmoid Biotechnologies Limited) was his employer and, pursuant to Irish Law, was entitled to the Inventions and the Applications.
- C. The parties to this assignment now wish to record their agreement to the inventorship position stated in Clause A, the Inventor wishes to assign his remaining title, if any, in the US and elsewhere to Sigmoid Pharma and, as a precaution against any rights remaining with the Inventor contrary to his intention, wish to effect assignment to Sigmoid Pharma of any and all right, title and interest of the Inventor, for the considerations recited below.

Operative Clauses


1. The inventor and Sigmoid Pharma hereby confirm their belief that the Inventor is the sole devisor of the Invention.
2. The Inventor and Sigmoid Pharma agree that, as between the Inventor and Sigmoid Pharma, the Inventions, the Applications and all related intellectual property rights (in particular the right to apply for and be granted patents for the Inventions in or for any part of the world, and the right to priority) are the property of Sigmoid Pharma pursuant to the Inventor's employment by Sigmoid Biotechnologies Limited, the circumstances of that employment and the operation of the law of the Republic of Ireland.
3. In consideration of the sum of €1.00 now paid by Sigmoid Pharma to the Inventor (receipt of which the Inventor hereby acknowledges) the Inventor hereby assigns absolutely to Sigmoid Pharma any and all right, title and interest he had in and to the Inventions and the Applications and the full and exclusive benefit thereof, including without limitation any and all future national phase, regional phase, divisional, continuing, substitute, renewal, reissue and all other applications and patents which:

- i. are derived directly or indirectly from at least one of the Applications; and/or
 - ii. claim priority from at least one of the Applications; and/or
 - iii. claim and/or disclose any of the Inventions.
4. Ivan Coulter hereby irrevocably appoints Sigmoid Pharma as Attorney in his name and on his behalf to execute and do any instrument or thing as may be required by Sigmoid Pharma to enable Sigmoid Pharma to enjoy the full benefit of the rights assigned by this Assignment and in favour of any third party a certificate signed by any Officer of Sigmoid Pharma that any instrument or act falls within such authority shall be conclusive evidence that such is the case.
5. This Agreement shall be governed by and interpreted in accordance with the law of the Republic of Ireland and the parties hereby submit to the non-exclusive jurisdiction of the courts of the Republic of Ireland.
6. This Agreement may be executed in any number of counterparts each of which when executed and delivered shall be an original and all the counterparts together shall constitute one and the same instrument.

IN WITNESS of which this Assignment has been executed and delivered the date and year first above written

Signed by Ivan Coulter
in the presence of:

Signature



Witness

Signature



Name:


Tien Ngkiem

Address:

17 Foxborough Court
Lucan
Co. Dublin
Ireland

Signed by Ivan Coulter,
Director, for and on behalf of
Sigmoid Pharma Limited

Signature



Witness

Signature



Name:

.....T.IEN NGHIEM.....

Address:

.....17 Foxborough Court
.....Lucan
.....Co. Dublin
.....Ireland.....

Schedule A**An Oral Pharmaceutical Composition (SIGM06 – HGF Ref P124804)**

PCT patent application IE2008/000040 (pub WO 2008/122967) and all national and regional applications and patents derived therefrom, including without limitation:

- US 12/594542
- European patent application 08719898.2
- Canadian patent application CA 2,683,415
- Japanese patent application 2010-501662
- Irish patent application 2008/0260
- Chinese patent application 2008 80018317.0
- Indian patent application 6470/DELNP/2009

Manufacture of Multiple Minicapsules (SIGM07 – HGF Ref P124827)

PCT application IE2008/000048 (pub WO 2008/132707) and all national and regional applications and patents derived therefrom, including without limitation:

- US patent application 12/597154
- European patent application 08738139.8
- Canadian patent application CA 2,685,118
- Irish patent application 2008/0324
- Japanese patent application 2010-504993

Pharmaceutical Nimodipine Compositions (SIGM08 – HGF Ref P124826)

PCT application IE2008/000051 (pub WO/2008/132710) and all national and regional applications and patents derived therefrom, including without limitation:

- US patent application 12/598,395
- European patent application 08738142.2
- Canadian CA 2,685,591
- Irish patent application 2008/0345
- Chinese patent application 200880018932.1
- Indian patent application 7066/DELNP/2009
- Japanese patent application

Combination Pharmaceutical Combinations (SIGM10 – HGF Ref P124727)

PCT patent application IE2008/000053 (pub WO/2008/132712) and all national and regional applications and patents derived therefrom, including without limitation:

- US patent application 12/598386
- European patent application 08738144.8

- Canadian patent application 2,685,593
- Irish patent application 2008/0349
- Chinese patent application 200880018808.5
- Indian patent application 7065/DELNP/2009
- Japanese patent application 2010-504995

Pharmaceutical Cyclosporin Compositions (SIGM11 – HGF Ref P124836)

PCT patent application IE2008/000038 (pub WO/2008/122965) and all national and regional applications and patents derived therefrom, including without limitation:

- US patent application 12/594534
- European patent application 08719896.6
- Canadian patent application 2,683,407
- Irish patent application 2008/0258
- Chinese patent application 200880016221.0
- Indian patent application 6472/DELNP/2009
- Japanese patent application 2010-501660

A Pharmaceutical Composition of Tacrolimus (SIGM12 – HGF Ref P124813)

PCT patent application IE2008/000039 (pub WO/2008/122966) and all national and regional applications and patents derived therefrom, including without limitation:

- US patent application 12/594553
- European patent application 08719897.4
- Canadian patent application 2683409
- Irish patent application 2008/0259
- Chinese patent application 200880016191.3
- Indian patent application 6471/ DELNP/2009
- Japanese patent application 2010-501661